What the FDA labels say about taking them together
Aripiprazole and paroxetine
Aripiprazole's FDA label of January 29, 2025 names paroxetine in its drug interactions section; the paroxetine labels PlainMeds reads (4) do not name aripiprazole. The aripiprazole label: “Reduce the ABILIFY dosage when administered concomitantly with a strong CYP3A4 inhibitor or a strong CYP2D6 inhibitor.”
Check it at the source: the aripiprazole FDA label on DailyMed (effective January 29, 2025, Otsuka America Pharmaceutical, Inc.); the paroxetine FDA label on DailyMed (effective February 12, 2026, Mylan Pharmaceuticals Inc.).
What does the aripiprazole label say about paroxetine?
Aripiprazole label, drug interactionsConcomitant Drug Name or Drug Class: Strong CYP3A4 Inhibitors (e.g., itraconazole, clarithromycin) or strong CYP2D6 inhibitors (e.g., quinidine, fluoxetine, paroxetine); Clinical Rationale: Concomitant use of ABILIFY with strong CYP3A4 or CYP2D6 inhibitors increased the exposure of aripiprazole compared to the use of ABILIFY alone [see ].; Clinical Recommendation: Reduce the ABILIFY dosage when administered concomitantly with a strong CYP3A4 inhibitor or a strong CYP2D6 inhibitor [see ].
Abilify Maintena label (Otsuka America Pharmaceutical, Inc., March 24, 2026), drug interactionsConcomitant Drug Name or Drug Class: Strong CYP3A4 Inhibitors (e.g., ketoconazole) or strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine); Clinical Rationale: The concomitant use of oral aripiprazole with strong CYP3A4 or CYP2D6 inhibitors increased the exposure of aripiprazole [see ].; Clinical Recommendation: With concomitant use of ABILIFY MAINTENA with a strong CYP3A4 inhibitor or CYP2D6 inhibitor for more than 14 days, reduce the ABILIFY MAINTENA dosage [see ].
Source: FDA drug label (Abilify Maintena, NDA202971), Otsuka America Pharmaceutical, Inc., effective March 24, 2026 (SPL set ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6), via openFDA
Source: FDA drug label (ABILIFY), Otsuka America Pharmaceutical, Inc., effective January 29, 2025 (SPL set c040bd1d-45b7-49f2-93ea-aed7220b30ac), via openFDA; the full label on DailyMed
What does the paroxetine label say about aripiprazole?
Paroxetine's label (effective February 12, 2026) and its 3 other brand-application labels do not name aripiprazole in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Paroxetine), Mylan Pharmaceuticals Inc., effective February 12, 2026 (SPL set 89dd7e24-85fc-4152-89ea-47ec2b48a1ed), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Aripiprazole | Paroxetine | |
|---|---|---|
| Labeled for | Depression, Bipolar disorder, Schizophrenia | Depression, Anxiety, Menopause symptoms |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.110 per tablet 5 mg tablet | $0.0611 per tablet 20 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once